Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment
<p dir="ltr">Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has signific...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , |
| Published: |
2019
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513516146262016 |
|---|---|
| author | Mohammad A. I. Al-Hatamleh (11564929) |
| author2 | Engku Nur Syafirah E.A.R. (18543943) Jennifer C. Boer (5813579) Khalid Ferji (1506778) Jean-Luc Six (1506784) Xin Chen (14149) Eyad Elkord (5396390) Magdalena Plebanski (21001) Rohimah Mohamud (5465972) |
| author2_role | author author author author author author author author |
| author_facet | Mohammad A. I. Al-Hatamleh (11564929) Engku Nur Syafirah E.A.R. (18543943) Jennifer C. Boer (5813579) Khalid Ferji (1506778) Jean-Luc Six (1506784) Xin Chen (14149) Eyad Elkord (5396390) Magdalena Plebanski (21001) Rohimah Mohamud (5465972) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammad A. I. Al-Hatamleh (11564929) Engku Nur Syafirah E.A.R. (18543943) Jennifer C. Boer (5813579) Khalid Ferji (1506778) Jean-Luc Six (1506784) Xin Chen (14149) Eyad Elkord (5396390) Magdalena Plebanski (21001) Rohimah Mohamud (5465972) |
| dc.date.none.fl_str_mv | 2019-12-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/cells9010033 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Synergistic_Effects_of_Nanomedicine_Targeting_TNFR2_and_DNA_Demethylation_Inhibitor_An_Opportunity_for_Cancer_Treatment/25808263 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biotechnology Oncology and carcinogenesis nanoparticles immunosuppressive regulatory T cells TNF immunotherapy |
| dc.title.none.fl_str_mv | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has significant implications in cancer progression, metastasis and immune evasion. Although nanomedicine has been extensively studied as a carrier of cancer immunotherapeutic agents, no study to date has investigated TNFR2-targeting nanomedicine in cancer treatment. From an epigenetic perspective, previous studies indicate that DNA demethylation might be responsible for high expressions of TNFR2 in cancer models. This perspective review discusses a novel therapeutic strategy based on nanomedicine that has the capacity to target TNFR2 along with inhibition of DNA demethylation. This approach may maximize the anti-cancer potential of nanomedicine-based immunotherapy and, consequently, markedly improve the outcomes of the management of patients with malignancy.</p><h2>Other Information</h2><p dir="ltr">Published in: Cells<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cells9010033" target="_blank">https://dx.doi.org/10.3390/cells9010033</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_8eff9af491fadd9d3a4288e624a5feef |
| identifier_str_mv | 10.3390/cells9010033 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25808263 |
| publishDate | 2019 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer TreatmentMohammad A. I. Al-Hatamleh (11564929)Engku Nur Syafirah E.A.R. (18543943)Jennifer C. Boer (5813579)Khalid Ferji (1506778)Jean-Luc Six (1506784)Xin Chen (14149)Eyad Elkord (5396390)Magdalena Plebanski (21001)Rohimah Mohamud (5465972)Biomedical and clinical sciencesMedical biotechnologyOncology and carcinogenesisnanoparticlesimmunosuppressiveregulatory T cellsTNFimmunotherapy<p dir="ltr">Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has significant implications in cancer progression, metastasis and immune evasion. Although nanomedicine has been extensively studied as a carrier of cancer immunotherapeutic agents, no study to date has investigated TNFR2-targeting nanomedicine in cancer treatment. From an epigenetic perspective, previous studies indicate that DNA demethylation might be responsible for high expressions of TNFR2 in cancer models. This perspective review discusses a novel therapeutic strategy based on nanomedicine that has the capacity to target TNFR2 along with inhibition of DNA demethylation. This approach may maximize the anti-cancer potential of nanomedicine-based immunotherapy and, consequently, markedly improve the outcomes of the management of patients with malignancy.</p><h2>Other Information</h2><p dir="ltr">Published in: Cells<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cells9010033" target="_blank">https://dx.doi.org/10.3390/cells9010033</a></p>2019-12-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/cells9010033https://figshare.com/articles/journal_contribution/Synergistic_Effects_of_Nanomedicine_Targeting_TNFR2_and_DNA_Demethylation_Inhibitor_An_Opportunity_for_Cancer_Treatment/25808263CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/258082632019-12-01T00:00:00Z |
| spellingShingle | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment Mohammad A. I. Al-Hatamleh (11564929) Biomedical and clinical sciences Medical biotechnology Oncology and carcinogenesis nanoparticles immunosuppressive regulatory T cells TNF immunotherapy |
| status_str | publishedVersion |
| title | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| title_full | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| title_fullStr | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| title_full_unstemmed | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| title_short | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| title_sort | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment |
| topic | Biomedical and clinical sciences Medical biotechnology Oncology and carcinogenesis nanoparticles immunosuppressive regulatory T cells TNF immunotherapy |